Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Filings indexed 1,237 across all filing types
Latest filing 2025-05-14 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2025-05-14 English
Please find enclosed herewith an advertisement published in the newspaper confirming the dispatch of the Postal Ballot Notice.
Regulatory Filings
2025-05-13 English
Copy of Newspaper Publication
Regulatory Filings
2025-05-13 English
Outcome of Board Meeting
Regulatory Filings
2025-05-12 English
Grant of 8,62,000 Stock Option under Bliss GVS Pharma Limited- Employee Stock Option Plan 2019
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the grant of stock options under an Employee Stock Options Plan (ESOP) by Bliss GVS Pharma Limited. It references compliance with SEBI Listing Regulations and SEBI circulars, and details the number of options granted, pricing formula, vesting schedule, and other terms. The document is an announcement of a corporate action related to employee stock options, specifically the grant of options and modification of the ESOP scheme. It does not contain financial statements, audit information, or detailed financial results. It is not a report or presentation but a regulatory announcement about capital/financing activity (stock options issuance). Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is about 5,099 characters, which is consistent with an announcement rather than a full report.
2025-05-12 English
Appointment of Internal Auditor and Secretarial Auditor.
Regulatory Filings
2025-05-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.